OncoMatch

OncoMatch/Clinical Trials/NCT04339036

CapTemY90 for Grade 2/3 NET Liver Metastases

Is NCT04339036 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Capecitabine Oral Product and Temozolomide Oral Product for neuroendocrine tumor grade 2.

Phase 2RecruitingAbramson Cancer Center at Penn MedicineNCT04339036Data as of May 2026

Treatment: Capecitabine Oral Product · Temozolomide Oral Product · transarterial radioembolization — This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone. A Grade 3 arm was added in 2025.

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroendocrine Tumor

Disease stage

Metastatic disease required

Grade: 23

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: transarterial embolization

Patients previously treated with transarterial embolization (with or without chemotherapy)

Cannot have received: radioembolization (Y-90 microspheres)

Patients previously treated...with radioembolization (Y-90 microspheres)

Lab requirements

Blood counts

platelets >100,000/mcL (may be corrected by transfusion), INR <1.6 (may be corrected by transfusion)

Kidney function

serum creatinine < 2.0 mg/dl

Liver function

Total bilirubin ≤ 2.0mg/dl, ALT, AST ≤5 times ULN, albumin ≥2.5g/dl

Adequate liver function as measured by: Total bilirubin ≤ 2.0mg/dl, ALT, AST ≤5 times ULN, albumin ≥2.5g/dl. Patients must have adequate organ and marrow function as defined below: platelets >100,000/mcL (may be corrected by transfusion), serum creatinine < 2.0 mg/dl, INR <1.6, (may be corrected by transfusion)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • UC San Diego · La Jolla, California
  • University of Miami Miller School of Medicine-Sylvester Cancer Center · Miami, Florida
  • Roswell Park Comprehensive Cancer Center · Buffalo, New York
  • University of Pennsylvania · Philadelphia, Pennsylvania

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify